

SupplementaryTable 1: Predictors of CD4+ T Cell Recovery After Month 12 of Suppressive ART

Characteristic	<u>Unadjusted</u>		<u>Adjusted</u>	
	Mean Δ in square root CD4 Count (cells/mm ³)	P Value	Mean Δ in square root CD4 Count (cells/mm ³)	P Value
Month 12 CD8+ T cell activation, <i>per 10 percentage-point increase in % CD38+ HLA-DR+ CD8+ T cells</i>	-0.6	0.032	0.19	0.39
Month 12 CD4+ T cell count, <i>per 100 cell/mm³ increase</i>	2.2	<0.001	1.9	<0.001
Pre-therapy CD4+ T cell count, <i>per 100 cell/mm³ increase</i>	2.2	<0.001	0.8	0.02
Pre-therapy Plasma HIV RNA level, <i>per log₁₀ copy/ml increase</i>	-1.0	0.023	-0.5	0.23
Female Gender	0.4	0.56	0.13	0.84
Per Month	0.17	<0.001	0.14	<0.001
Month 12 CD8+ T cell activation x Month	-0.01	0.24	-0.02	0.075
Month 12 CD4+ T cell count x Month	-0.017	0.044	-0.03	0.001
Pre-therapy CD4+ T cell count x Month	0.0096	0.40	0.03	0.03
Pre-therapy Plasma HIV RNA level x Month	0.01	0.55	0.04	0.07
Female Gender x Month	0.05	0.044	0.05	0.12

Supplementary Table 2: Predictors of Late Mortality Among HIV-infected Ugandans with Plasma HIV RNA Levels <400 copies/ml at Month 6 of ART

Characteristic	<u>Unadjusted</u>		<u>Adjusted</u>	
	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value
Pre-therapy CD4+ T cell count, <i>per 100 cell/mm³ increase</i>	0.43 (0.17 to 1.11)	0.081	0.42 (0.14 to 1.29)	0.13
Month 6 CD8+ T cell activation level, <i>per 10 percentage-point increase in % CD38+ HLA-DR+ CD8+ T cells</i>	1.65 (1.05 to 2.59)	0.029	1.62 (1.01 to 2.61)	0.048